A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
← catalyst calendarNCT05067790 · readout in 400 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
45actual
Sites
22
Countries
Germany, Hungary, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-21 | actual | When the study began enrolling |
| Primary completion | 2027-09-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-24 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Spinal Muscular Atrophy
Intervention
- Drug: Nusinersen — also filed as BIIB058, Spinraza
Primary outcome
what the primary-completion date above is the date OFChange in Total Revised Upper Limb Module (RULM) Score
measured Up to Day 855
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed